TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00790842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given by mouth days 1-21 of a 28-day cycle. There is a 7 day rest (days 22-28). Continue until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given by mouth days 1-21 of a 28-day cycle. There is a 7 day rest (days 22-28). Continue until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given by mouth days 1-21 of a 28-day cycle. There is a 7 day rest (days 22-28). Continue until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg given by mouth days 1, 8, 15 and 22 of a 28-day cycle. Continue until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg given by mouth days 1, 8, 15 and 22 of a 28-day cycle. Continue until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg given by mouth days 1, 8, 15 and 22 of a 28-day cycle. Continue until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulants
Description: Anticoagulation consisted of aspirin at either 81 mg/day or 325 mg/day at the physician's discretion. Heparin, low molecular weight heparin, or coumadin could be used if the patient was intolerant to aspirin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulants
Description: Anticoagulation consisted of aspirin at either 81 mg/day or 325 mg/day at the physician's discretion. Heparin, low molecular weight heparin, or coumadin could be used if the patient was intolerant to aspirin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulants
Description: Anticoagulation consisted of aspirin at either 81 mg/day or 325 mg/day at the physician's discretion. Heparin, low molecular weight heparin, or coumadin could be used if the patient was intolerant to aspirin.
Study: NCT03869047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine +bupivacaine
Description: patients will receive combined general anesthesia and Quadratuslumborum block( transincisional ie before wound closure)with 19 mL of bupivacaine 0.20%plus 1 mic/kg of dexmedetomidine, total volume 20 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: patients will receive combined general anesthesia and quadratus lumborum block (transincisional) with 20 ml of bupivacaine 0.20% .
Study: NCT01471288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carum Cravi
Description: 40mg/kg of body weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carum Cravi
Description: 40mg/kg of body weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01052337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anaesthetics: sevofluorane
Description: 0.5%of sevofluorane with air

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anaesthetics: sevofluorane
Description: 0.5%of sevofluorane with air
Study: NCT04444453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Pedometer
Description: Pedometer worn on wrist
Study: NCT04442802

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty
Description: Under local anesthesia the percutaneous arterial access will be created. Digital subtraction angiography of the whole limb will be performed. Occlusive-stenotic lesion of the superficial femoral and / or popliteal artery will be crossed with a guidewire. The plain old (non drug-eluting) will be positioned in the affected arterial segment and inflated up to nominal pressure. After balloon deflation and extraction the completion angiography will be performed. Presence (yes/no) and severity (grades A-B or C-F according to NHLBI classification) of dissection will be assessed independently by 3 study investigators basing on DSA images in 2 directions. Decision to classify the dissection as severe (grade C-F) and to perform the bailout stenting will be done by the agreement between at least 2 from 3 investigators.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous transluminal angioplasty
Description: Under local anesthesia the percutaneous arterial access will be created. Digital subtraction angiography of the whole limb will be performed. Occlusive-stenotic lesion of the superficial femoral and / or popliteal artery will be crossed with a guidewire. The plain old (non drug-eluting) will be positioned in the affected arterial segment and inflated up to nominal pressure. After balloon deflation and extraction the completion angiography will be performed. Presence (yes/no) and severity (grades A-B or C-F according to NHLBI classification) of dissection will be assessed independently by 3 study investigators basing on DSA images in 2 directions. Decision to classify the dissection as severe (grade C-F) and to perform the bailout stenting will be done by the agreement between at least 2 from 3 investigators.
Study: NCT03682770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab will be administered subcutaneously (SC) in a single-use, pre-filled glass syringe every two weeks (Q2W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching dupilumab
Description: Placebo matching dupilumab is prepared in the same formulation without the addition of protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR101
Description: AR101 will be provided in dose-escalating capsules and then sachets during maintenance phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR101
Description: AR101 will be provided in dose-escalating capsules and then sachets during maintenance phase
Study: NCT03328091

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional pre-test genetic counseling
Description: Participant meets with a genetic counselor at the Center for Cancer Genetics and Prevention and traditional pre-test cancer genetic counseling is provided

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-test video education
Description: The video is designed to mirror the educational components of a traditional genetic counseling visit
Study: NCT05240027

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Vape use survey
Description: pre \& post test surveys
Study: NCT03802292

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: YQ23
Description: Single dose of YQ23 delivered via intravenous route. Ascending dose levels will be evaluated

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Single dose of the matching placebo delivered via intravenous route.
Study: NCT03760042

Intervention type: DRUG
Group type: OTHER
Intervention: Within-Subject Active vs Placebo Topical Applications
Description: Crisaborole 2% ointment (right side) and Placebo vehicle ointment (left side)

Intervention type: DRUG
Group type: OTHER
Intervention: Within-Subject Active vs. Placebo Topical Applications
Description: Crisaborole 2% ointment (left side) and Placebo vehicle ointment (right side)
Study: NCT01537705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuron012703 (Medical Food)
Description: 2 capsules twice daily for sixty days.
Study: NCT02783807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyenez Retinal Camera v200

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Volk Pictor Ret 1
Study: NCT03262844

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Conservative treatment
Description: The conservative treatment group will be given diet and nursing guidance, then the drug treatment or physiotherapy will be given according to the conditions of patients. Patients with bladder dysfunction will be guided to perform routine intermittent catheterization with help of their parents.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capsule surgery
Description: In the multiple segments of the spine, articular facet joint and intervertebral disc will be resected to achieve the effect of decompression.~Specific surgical segments, osteotomy range, decompression degree of each patient needs to be designed individually.
Study: NCT03008057

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: vitamin D supplement, 4000 IU tablet daily , one time a day, for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D placebo
Description: vitamin D placebo tablet (Containing starch powder), one time a day, for 3 months
Study: NCT00774566

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PV-Isolation RF
Description: Radiofrequency

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PV-Isolation Cryo
Description: Cryo-Balloon
Study: NCT01000792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: The study drug is Xyzal® 5 mg (API: levocetirizine dihydrochloride). 28 film tablets will be dispensed. Oral intake should be performed once daily (administration in the evening).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: Levocetirizine
Study: NCT02314559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manual titration of propofol
Description: One group will be sedated with a manual titration technique: here the titration of propofol is done manually by the anesthetist. Dosages may range between 50 and 400mg, given by boluses of 20-50mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Target controlled infusion of propofol
Description: The other group will be sedated with a target controlled infusion technique (pump, marsh or Schneider). The anesthetist can titrate indirectly by adjusting the target controlled infusion to achieve adequate sedation. The concentrations of propofol may vary between 2 and 6 µg/ml, achieved by increments of 0.5-1.5 µg/ml.
Study: NCT00976924

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood glucose monitor
Description: Blood glucose monitor is used to monitor the blood glucose level of the human-being.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: blood glucose monitor
Description: Blood glucose monitor is used to monitor the blood glucose level of the human-being.
Study: NCT04242524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circadian Clock Alignment
Description: Use timed lights and meals to align the circadian clock

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Circadian Clock Control
Description: No circadian clock alignment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Circadian Clock Control
Description: No circadian clock alignment
Study: NCT02424877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SandRA
Description: SandRA software sends SMS messages to a patient asking questions about the usage and adverse effects of prescribed drugs and about the severity of rheumatoid arthritis. The answer messages are interpreted automatically.
Study: NCT02754440

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trima Accel System with Version 7.0 Software
Description: Platelet Apheresis Procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trima Accel System with Version 7.0 Software
Description: Platelet Apheresis Procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trima Accel System with Version 7.0 Software
Description: Platelet Apheresis Procedure
Study: NCT03317015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone XRG5029
Description: Pharmaceutical form: spray solution~Route of administration: nasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone
Description: Pharmaceutical form: spray solution~Route of administration: nasal
Study: NCT00560170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin (Zocor)
Description: 40mg of Simvastatin (n=20) orally per-day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10mg/10mg of Ezetimibe/Simvastatin (Vytorin)
Description: 10mg/10mg of Ezetimibe/Simvastatin (n=20) orally per-day for 28 days
Study: NCT00500513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Scans
Description: CT scan performed weekly to measure how much the tumor moves + additional pulmonary function measurements.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implanted markers
Description: Implanted radio-opaque fiducial markers, diameter of 1.0 - 2.0 mm, inserted through a catheter at several chest locations using a flexible bronchoscope

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Treatment (RT)
Description: Radiotherapy incorporating respiratory treatment delivery
Study: NCT03677557

Intervention type: DRUG
Group type: OTHER
Intervention: 16,5% Cutaquig
Description: Participants with primary or secondary immunodefiiciney disease and who do not tolerate other immunoglobulin treatments will be asked to use 16.5% Cutaquig
Study: NCT02328638

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Parent Education Program
Description: The PEP intervention consists of didactic sessions regarding basic information about Autism Spectrum Disorders.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Manual-based Behavioral Treatment
Description: The Manual-based Interdisciplinary Behavioral Treatment consists of nutritional and behavioral interventions to improve dietary intake (increase water, decrease sweetened beverages and snack foods, improve balanced diet), increase exercise, and teach behavioral strategies to address barriers to these goals.
Study: NCT02647996

Intervention type: PROCEDURE
Intervention: MRI: functional (resting state) and structural (DTI)
Description: One hour brain MRI recording without active task for the patient, no sedation

Intervention type: PROCEDURE
Intervention: MRI: functional (resting state) and structural (DTI)
Description: One hour brain MRI recording without active task for the patient, no sedation
Study: NCT02577718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin-citrate-ethanol (NiCE)
Description: Lock solution instilled in catheter lumens for 2 hours then flushed. Administration for up to 30 days, daily as in-patient or once weekly as out-patient
Study: NCT02849899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Description: Galvus is prescribed as recommended by the marketing authorization. In adults, the recommended dose of Galvus is 100 mg per day (one tablet in the morning and another in the evening).~In patients with moderate or severe kidney problems, the recommended dose is 50 mg once daily (one tablet in the morning).~Patients with creatinine clearance greater than 50 ml/min the vildalgliptin dose will be 100 mg/day. For those whose clearance is less than 50 ml/min, the daily dose is 50 mg. The creatinine clearance will be measured each week.~The treatment duration will be 3 months, divided into 2 months of complete treatment and one month of cessation treatment with half dose of vildagliptin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is the same as Galvus (packaging, shape, color, registration) but will contain only excipient. The given dose will also be identical.
Study: NCT00275509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 2 gm/day. Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 2 gm/day. Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: To achieve serum level of 8-10 ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: To achieve serum level of 8-10 ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 100 mg intra-operatively, and 25 mg every 6h post-operatively for six doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 100 mg intra-operatively, and 25 mg every 6h post-operatively for six doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Taper over three months to 5 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Taper over three months to 5 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytogam
Description: Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytogam
Description: Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered
Study: NCT01967576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: 5 mg twice a day on a 28-day cycle.
Study: NCT02874989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib + Quercetin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01814267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemedicine
Description: Intervention group: care and follow-up through telemedicine (e-consultations)~* 1 hospital consultation at inclusion time, week 0~* then every 15 days, after the transmission of medical data and photos via internet by the nurse, telemedicine e-consultations until the wound has healed (week 2,week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 18, week 20, week 22, week 24 : end point study), i.e. 12 e-consultations over a 6-month period.~* 1 hospital consultation to validate that the wound is well-healed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: conventional group: iterative diabetes physicians consultations at hospital~* 1 consultation at inclusion time, week 0~* 1 consultation 2 weeks after inclusion, week 2~* 1 consultation per month until the wound has healed (week 4, week 8, week 12, week 16, week 20, week 24: end-point study), i.e. 6 consultations over a 6-month period~* 1 consultation to validate that the wound is well-healed
Study: NCT01686399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional and Activity Promotion
Description: Multi disciplinary nutritional and behavioral messages to improve diet and activity levels
Study: NCT02772367

Intervention type: PROCEDURE
Intervention: skin punch biopsy
Study: NCT02858362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezutromid
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezutromid
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezutromid
Description: Administered orally.
Study: NCT03441815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02064101

Intervention type: PROCEDURE
Intervention: Spinal Fusion
Description: The investigators are studying the use of triggered EMG via the IPC POWEREASE screwdriver (Product Codes HBE, HWE, GWF) during spinal fusion surgery in adolescent idiopathic scoliosis by comparing it to the traditional triggered EMG OrthoMon probe system (Product Codes GWF, IKN).
Study: NCT02369796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-448
Description: TAK-448 solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-448
Description: TAK-448 solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-448
Description: TAK-448 solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-448
Description: TAK-448 solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-448
Description: TAK-448 solution for subcutaneous injection
Study: NCT03281200

Intervention type: DRUG
Intervention: L - Antineoplastic and immunomodulating agents
Description: L - Antineoplastic and immunomodulating agents

Intervention type: DRUG
Intervention: L01 - Antineoplastic agents
Description: L01 - Antineoplastic agents

Intervention type: DRUG
Intervention: L01X - Other antineoplastic agents
Description: L01X - Other antineoplastic agents

Intervention type: DRUG
Intervention: L01XE - Protein kinase inhibitors
Description: L01XE - Protein kinase inhibitors

Intervention type: DRUG
Intervention: L01XE31 - Nintedanib
Description: L01XE31 - Nintedanib
Study: NCT04601649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Talk
Description: The study is designed to provide education, support, and referrals for PrEP.
Study: NCT03903588

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: Imaging of the Retina

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: Imaging of the Retina

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: Imaging of the Retina
Study: NCT01823016

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168
Description: JNJ-38518168, 30 mg tablet, taken once daily
Study: NCT03143062

Intervention type: DIAGNOSTIC_TEST
Intervention: NEWS
Description: NEWS

Intervention type: DIAGNOSTIC_TEST
Intervention: NEWS
Description: NEWS
Study: NCT02094924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK587323
Description: Single dose of FDC tablet formulation to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK587323
Description: Single dose of FDC tablet formulation to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg
Description: Single dose of FDC tablet formulation to be taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg
Description: Single dose of FDC tablet formulation to be taken orally